EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Population pharmacokinetics of rivaroxaban after transjugular intrahepatic portosystemic shunt

Min Jia, Yiming Chai, Yuan Gao, Changyou Jing, Kunlei Zhu, Tong Zhu, Liang Wang, Aili Sun, Jun Yang, Yanqiu Zhu, Yingmei Feng, Yu Cao und 1 weitere

European Journal of Clinical Pharmacology · 2026-04 · 82 (4)

DOI: 10.1007/s00228-026-04034-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 24.03.2026. Verfasst von Min Jia und 12 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, No. 8, Xi Tou Tiao, Youanmen Wai, Fengtai District, Beijing, 100…. Hauptthemen laut MEDLINE: Portasystemic Shunt, Transjugular Intrahepatic, Rivaroxaban, Models, Biological, Factor Xa Inhibitors. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Institute of Hepatology Reform and Development Project-Beijing Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Rivaroxaban, a new direct oral anticoagulant (DOAC), has demonstrated better efficacy and safety than traditional anticoagulants. Individualized anticoagulation is crucial in patients with a transjugular intrahepatic portosystemic shunt (TIPS) and portal vein hypercoagulability to avoid stent thrombosis. As TIPS shunts portal blood directly into the systemic circulation and may substantially affect the first-pass extraction/distribution of direct oral anticoagulants, no population prospective pharmacokinetic studies have been published in patients undergoing TIPS placement so far. The goal of this study was to establish a PopPK model for rivaroxaban in post-TIPS patients, investigate clinical covariate effects on PK, and provide an optimized dosing regimen.

Methods

In this single-centre prospective study, 39 adult patients underwent TIPS and received rivaroxaban 5 or 10 mg once daily thereafter. Population PK analysis was conducted in NONMEM with 131 plasma concentrations available from 38 evaluable patients (median age: 56 years; median body weight: 63.8 kg). Parameterized model was then applied to simulate steady-state exposure of 5, 7.5, 10, and 15 mg once daily regimen.

Results

The final PopPK model was based on a one-compartment with sequential zero-order followed by first-order absorption kinetics, and included the effects of an absorption lag time and linear elimination. The apparent clearance and volume of distribution were 7.48 L/h and 4.75 L, respectively. Based on patient-specific simulations of 38 subjects, at the 5 mg/day dose, an exposure within predefined limits was potentially preserved in 96.7% of the cases vs. 62.5% for the 10 mg/day (thresholds: AUC ss,24 ≤ 1.77 mg·h/L and C max, ss ≤ 140 µg/L). This trend was confirmed by Monte-Carlo simulations in 1,000 virtual patients and suggests TDM when the higher dosage is given.

Conclusions

This PopPK model provides an initial characterisation of rivaroxaban disposition in post-TIPS patients and reveals a markedly reduced apparent V/F relative to non-TIPS populations. The 5 mg once-daily regimen is generally safe, while the 10 mg dose may be considered with therapeutic drug monitoring to account for substantial inter-individual pharmacokinetic variability in post-TIPS patients.

Trial registration

Chinese Clinical Trial Registry, ChiCTR (ChiCTR2300073784); registered 20 July 2023.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Portasystemic Shunt, Transjugular IntrahepaticRivaroxabanModels, BiologicalFactor Xa InhibitorsHumansFemaleMiddle AgedMaleProspective StudiesAdultAged

Stichwörter der Autor:innen

Model-informed dosingPopulation pharmacokinetics (PopPK)RivaroxabanTransjugular intrahepatic portosystemic shunt (TIPS)

Substanzen

RivaroxabanFactor Xa Inhibitors

Autor:innen und Institutionen

  • Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, No. 8, Xi Tou Tiao, Youanmen Wai, Fengtai District, Beijing, 100069, China.
  • Quality Management Office for Clinical Research, Beijing Youan Hospital, Capital Medical University, No. 8, Xi Tou Tiao, Youanmen Wai, Fengtai District, Beijing, 100069, China.
  • Zhongchuang Huiming (Beijing) Medical Technology Co., Ltd, No. 223-224, 5th Floor, No. 181, Laogongying Village, Liulimiao Town, Huairou District, Beijing, 101405, China.
  • Liver Disease Center, Beijing Youan Hospital, Capital Medical University, No. 8, Xi Tou Tiao, Youanmen Wai, Fengtai District, Beijing, 100069, China.
  • Hepatic Disease and Oncology Minimally Invasive Interventional Center, Beijing Youan Hospital, Capital Medical University, No. 8, Xi Tou Tiao, Youanmen Wai, Fengtai District, Beijing, 100069, China.
  • National Clinical Trial Institution for Drugs, Beijing Youan Hospital, Capital Medical University, No. 8, Xi Tou Tiao, Youanmen Wai, Fengtai District, Beijing, 100069, China.

Förderung

  • Beijing Institute of Hepatology Reform and Development Project-Beijing Municipal Health Commission

Zitieren

APA

Jia, M., Chai, Y., Gao, Y., Jing, C., Zhu, K., Zhu, T., Wang, L., Sun, A., Yang, J., Zhu, Y., Feng, Y., Cao, Y., & Li, J. (2026). Population pharmacokinetics of rivaroxaban after transjugular intrahepatic portosystemic shunt. European Journal of Clinical Pharmacology, 82(4). https://doi.org/10.1007/s00228-026-04034-6

Vancouver

Jia M, Chai Y, Gao Y, Jing C, Zhu K, Zhu T, et al. Population pharmacokinetics of rivaroxaban after transjugular intrahepatic portosystemic shunt. European Journal of Clinical Pharmacology. 2026;82(4). doi:10.1007/s00228-026-04034-6

BibTeX
@article{Jia2026,
  author = {Jia, Min and Chai, Yiming and Gao, Yuan and Jing, Changyou and Zhu, Kunlei and Zhu, Tong and Wang, Liang and Sun, Aili and Yang, Jun and Zhu, Yanqiu and Feng, Yingmei and Cao, Yu and Li, Jianjun},
  title = {Population pharmacokinetics of rivaroxaban after transjugular intrahepatic portosystemic shunt},
  journal = {European Journal of Clinical Pharmacology},
  year = {2026},
  volume = {82},
  number = {4},
  doi = {10.1007/s00228-026-04034-6}
}
Kostenlos starten →